AMOXIL
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Jan 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
AMOXIL by GSK is drug. Approved for the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: 1. First approved in 1974.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMOXIL is an oral amoxicillin capsule, a beta-lactam antibiotic used to treat infections caused by susceptible gram-positive and gram-negative bacteria. It works by inhibiting bacterial cell wall biosynthesis, leading to bactericidal activity during active multiplication. The drug is rapidly absorbed orally and achieves therapeutic levels across most body tissues within 1-2 hours.
LOE Approaching
As a mature antibiotic approaching loss of exclusivity, AMOXIL brand teams focus on lifecycle management and generic transition planning with smaller commercial footprints than growth-stage products.
Mechanism of Action
drug. [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption: Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of Amoxicillin from the tablets and suspension of Amoxicillin has been partially…
Worked on AMOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.